Clinical trial

Multicenter Clinical and Basic Research on the Prevention and Treatment of 2019-nCoV by Integrated Traditional Chinese and Western Medicine

Name
ZhejiangCMU 2020-KL-0601-1
Description
According to the comprehensive evaluation, the completion of vaccination and the prevention and treatment strategy of integrated traditional Chinese and western medicine have obvious advantages in improving the symptoms of infection in patients with autoimmune diseases, shortening the course of disease and controlling disease activity, and can play a positive role in the whole process of epidemic prevention and treatment. Now the investigators plan to conduct multi-center clinical and basic research to observe the preventive effect and safety of the vaccine on COVID-19, as well as the preventive effect of the combination of traditional Chinese medicine, in order to obtain high-quality evidence-based evidence and provide scientific basis for the clinical value of the drug.
Trial arms
Trial start
2020-06-01
Estimated PCD
2024-06-01
Trial end
2024-12-01
Status
Recruiting
Treatment
the inactivated COVID-19 vaccines
receive the doses of inactivated COVID-19 vaccines
Arms:
healthy controls, the vaccinated patients with ADs
Size
1200
Primary endpoint
Incidence of local and systemic adverse events
3 years
Concentration of anti-SARS-CoV-2 spike protein
3 years
Infection rate of COVID-19
3 years
Eligibility criteria
Inclusion Criteria: * ≥18 years old * The ADs group were diagnosed with autoimmune diseases according to the following inclusion criteria: rheumatoid arthritis (RA) / American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) 2010 classification criteria; ankylosing spondylitis (AS) / the 1984 modified New York criteria; systemic lupus erythematosus (SLE) / 2019 EULAR/ACR classification criteria; Sjögren's Syndrome (SS) / 2016 ACR/EULAR Classification Criteria; systemic vasculitis / Chapel Hill Consensus Conference definitions; idiopathic inflammatory myositis (IIM) / 2017 EULAR/ACR classification criteria; psoriatic arthritis (PsA) / 2006 Classification Criteria for PsA; systemic sclerosis (SSc) / 2013 ACR/EULAR collaborative initiative; polymyalgia rheumatica (PMR) / 2012 provisional classification criteria. * The HC group were volunteers who did not have history of autoimmune diseases and did not receive immunosuppressive therapy. Exclusion Criteria: * history of COVID-19 infection * history of vaccination allergy * history of mental disabilities * pregnancy * unwillingness to sign informed consent.
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'PROSPECTIVE'}, 'bioSpec': {'retention': 'SAMPLES_WITHOUT_DNA', 'description': 'blood samples and urine samples'}, 'enrollmentInfo': {'count': 1200, 'type': 'ESTIMATED'}}
Updated at
2023-10-24

1 organization

1 product

2 indications

Indication
COVID-19